Find My Journal

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, N. Niederle, A. Rost, Heinz‐Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Dominik Paul Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing

The Lancet Oncology, 2014

Klinikum St. Marien Amberg, Bayreuth Medical Center, University of Applied Sciences Landshut, Krankenhaus Nordwest, Lukaskrankenhaus, Klinikum Magdeburg, Klinikum Weiden, Comprehensive Cancer Center Vienna, Medical University of Vienna, Klinikum Chemnitz, Klinikum Stuttgart, Westpfalz Klinikum, Klinikum Leverkusen, Klinikum Darmstadt, Klinikum Fulda, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Jena University Hospital, Ludwig-Maximilians-Universität München

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

1728

Citations

View on Google Scholar